摘要
Abstract
Objective:To study the clinicopathologic features,diagnosis,differential diagnosis and prognosis of intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).Methods:A total of 20 cases of intracranial SFT/HPC were enrolled in this study.The clinical data,pathologic characteristics and immunophenotype were studied and relevant literatures were reviewed.Results:Of these patients,12 cases were male and 8 were female,with an average age of 4.8.45 years.Seven cases received meningioma resection 6-19 years before.According to the latest 2016 WHO classification,there were 1 case of grade Ⅰ,13 cases of grade Ⅱ and 6 cases of grade Ⅲ.Immunohisochemically,tumor cells of all specimen were positive for vimentin,bcl-2,CD34 and STAT6,and were negative for EMA,AE1/AE3,S-100,CD31 and factor Ⅷ.The cells of grade Ⅰ case were strong and diffusely positive for CD34,while the cells of grade Ⅱ and grade Ⅲ cases had weak expression and patchy distribution of CD34.Ki-67 proliferation index ranged from 3％ to 30％.Fifteen of the 20 patients were followed-up for 5 months to 19 years.During this period,5 cases had disease recurrence,and 13 received postoperative radiotherapy,while 2 case did not receive any therapy.Up to March 2017,all cases were survived.Conclusions:According to the latest releas from WHO,SFT and HPC are classified as the same type of tumor,and immunohistochemistry staining of CD34 and ki-67 may be useful to grading and differential diagnosis of SFT/HPC.关键词
颅内孤立性纤维性肿瘤/血管周细胞瘤/免疫组织化学/鉴别诊断Key words
Solitary fibrous tumor/hemangiopericytoma/Immunohistochemistry/Differential diagnosis分类
医药卫生
